Human Facilitating Cells Enhance Stem Cell Engraftment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic protocols for hematopoietic stem cell transplantation face challenges in achieving long-term engraftment and donor-specific tolerance, often requiring harsh conditioning regimens and risking graft-versus-host disease.

Innovation Solution

The use of human facilitating cells (hFCs), specifically characterized by phenotypes such as CD8+/alpha beta TCR−/CD56dim/neg and CD8+/alpha beta TCR−/CD56bright, which are combined with hematopoietic stem cells to enhance engraftment and induce donor-specific tolerance, reducing the need for aggressive conditioning and minimizing graft-versus-host disease.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If harsh conditioning regimens are used to achieve long-term engraftment, then engraftment success is improved, but graft-versus-host disease risk increases

Engineering Contradiction:

Improveengraftment successVSAvoidgraft-versus-host disease risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces facilitating cells as an intermediary component that mediates between the transplant and the host immune system. These cells enable successful engraftment while simultaneously inducing donor-specific tolerance, thereby preventing graft-versus-host disease without requiring harsh conditioning regimens.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the immunological parameters of the transplant by including facilitating cells with specific phenotypes (CD8+/alpha beta TCR-/CD56dim/neg and CD8+/alpha beta TCR-/CD56bright). This parameter change allows the transplant to achieve both engraftment and tolerance induction, resolving the contradiction between engraftment success and GVHD prevention.

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If aggressive conditioning is applied to ensure engraftment, then engraftment durability is improved, but patient morbidity increases

Engineering Contradiction:

Improveengraftment durabilityVSAvoidpatient morbidity

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

Facilitating cells serve as a protective intermediary that enables durable engraftment through immunological mechanisms rather than aggressive conditioning. These cells induce donor-specific tolerance, allowing long-term survival without the morbidity associated with harsh regimens.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If high levels of immunosuppression are used to prevent rejection, then transplant acceptance is improved, but infection risk increases

Engineering Contradiction:

Improvetransplant acceptanceVSAvoidinfection risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the immunological parameter from broad immunosuppression to donor-specific tolerance. By including facilitating cells that induce antigen-specific tolerance, the system achieves transplant acceptance without the need for high-level non-specific immunosuppression, thereby reducing infection risk.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS9452184B2Human facilitating cells

Publication Date: 2016.09.27 UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC

AI summary

The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.